SM
VKTX icon

Sabby Management’s Viking Therapeutics VKTX Stock Holding History

Sabby Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,873
Closed -$6.75M – 143
2018
Q3 		$6.75M Buy
+3,873
New +$46.1K 0.86% 22

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sabby Management's VKTX Position: Q1 2019 in Review

Sabby Management sold out of Viking Therapeutics (VKTX) in Q1 2019, closing a stake of 72,500 shares — an estimated $607K sold.

Sabby Management first reported a position in VKTX in Q2 2017 and held it in 3 quarters. The position peaked at $2.85M in Q3 2018. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

  • Sabby Management reported no remaining Viking Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Sabby Management sold 72,500 Viking Therapeutics shares in Q1 2019, an estimated $607K.
  • Sabby Management first reported a position in Viking Therapeutics in Q2 2017 and held it in 3 quarters.
  • Sabby Management's Viking Therapeutics position peaked at $2.85M in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.